Auron Therapeutics Inc. has received FDA clearance of its IND application for its oral KAT2A/B degrader AUTX-703 in hematological malignancies. A phase I proof-of-concept trial in acute myeloid ...

Acute leukemia, a type of cancer that affects the blood and bone marrow, can present with a variety of symptoms, including musculoskeletal (MSK) manifestations. In pediatric patients, these ...

In particular, acute myeloid leukemia (AML) has been shown to undergo ... resequencing of all time point samples as well as an oral swab sample. Two platforms were used: PGM (Personal Genome ...

The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed acute myeloid leukemia (AML). A research team from Columbia Engineering and ...

Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies,” published in the February 2025 issue of American Journal of Hematology by Senapati et ...

The disease manifests in various subtypes, the most common being acute lymphoblastic leukemia (ALL) and acute myeloid ...